ELV

Elevance Health raised its 2026 earnings baseline to at least $26.75 per share, driven by favorable claims in Individual ACA plans and improved full-year outlook. The company's Carelon healthcare services unit reduced avoidable hospital admissions by 15% through targeted cancer care programs, while integrated pharmacy and medical coverage is generating member savings of up to $100 per month. Management expects broad-based operating improvements to continue into future periods, positioning the company for sustainable long-term earnings growth.

Elevance Health (ELV) has reached a new 52-week high of $440.67, up 9.4% over the past month and 25.6% year-to-date, outperforming its sector. The company has a strong earnings track record with a recent beat of $6.99 EPS versus $4.66 consensus estimate. With a Zacks Rank #2 (Buy), Value Score of A, and reasonable valuation metrics, analysts suggest the stock still has room to run despite recent gains.

Elevance Health reported Q3 2026 adjusted EPS of $6.99, significantly beating estimates by 50%, with revenue reaching $50.4B. The Carelon segment drove growth with 5.4% revenue increase and 17.2% operating gain growth. The company raised its 2026 adjusted EPS guidance to at least $29.00 and increased its earnings baseline to at least $26.75.